Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis

Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis

Objective: to perform cost-effectiveness analysis of the treatment for adult patients with psoriatic arthritis (PsA) with a Russian interleukin- 17А inhibitor netakimab in comparison with other biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic disease-modifying antirheu...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Rudakova, D. G. Tolkacheva, V. D. Sokolova
Format: Article
Language:Russian
Published: IRBIS LLC 2021-07-01
Series:Фармакоэкономика
Subjects:
psoriatic arthritis
netakimab
cost-effectiveness analysis
budget impact analysis
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/520
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items